Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 21Endocrine 21Thoracic 2Sarcoma 2NET 2Gastrointestinal 2CNS 2Plasma cell 1Other hematologic neoplasm 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 872Neoplasms, Plasma Cell 162Lymphoma, Non-Hodgkin 139Lymphoma 135Hodgkin Disease 134Leukemia, Lymphocytic, Chronic, B-Cell 118Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Myelodysplastic Syndromes 103Recurrence 101Leukemia, Myeloid, Acute 99Leukemia 94Lymphoma, Mantle-Cell 80Lymphoma, Large B-Cell, Diffuse 76Lymphoma, Follicular 73Myeloproliferative Disorders 69Lymphoma, B-Cell, Marginal Zone 69Hematologic Neoplasms 64Burkitt Lymphoma 64Primary Myelofibrosis 57Lymphoma, Large-Cell, Immunoblastic 55Waldenstrom Macroglobulinemia 52Leukemia, Myelogenous, Chronic, BCR-ABL Positive 52Leukemia, Myeloid, Chronic-Phase 46Lymphoma, T-Cell, Cutaneous 44Immunoglobulin Light-chain Amyloidosis 43Congenital Abnormalities 43Neoplasms 41Leukemia, Myelomonocytic, Chronic 41Leukemia, Myeloid, Accelerated Phase 40Sezary Syndrome 38

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Carcinoma, Anaplastic × Plasma cell × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡